[1] Salgia R,Singal AG.Hepatocellular carcinoma and other liver lesions. Med Clin North Am,2014,98(1):103-118. [2] Kumar N,Khakoo SI.Hepatocellular carcinoma:prospects for NK cell immunotherapy. HLA,2018,12(2):138-144. [3] Tahmasebi Birgani M,Carloni V.Tumor microenvironment,a paradigm in hepatocellular carcinoma progression and therapy. Int J Mol Sci,2017,18:405. [4] Chassaing B,Etienne-Mesmin L,Gewirtz AT.Microbiota-liver axis in hepatic disease.Hepatology,2014,59(1):328-339. [5] Rolas L,Makhezer N,Hadjoudj S,et al.Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. Hepatology,2013,57(3):1163-1171. [6] Minemura M,Shimizu Y.Gut microbiota and liver diseases. World J Gastroenterol,2015,21(6):1231-1238. [7] Yamada S,Takashina Y,Watanabe M,et al.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepato-cellular carcinoma in mice. Oncotarget,2018,9(11):9925-9939. [8] Wagh-Ray A,Murali AR,Menon KN.Hepatocellular carcinoma:From diagnosis to treatment. World J Hepatol,2015,7(8): 1020-1029. [9] Zuo CH,Xia M,Liu JS,et al.Transcatheter arterial chemoembolization combined with interferon-αis safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev,2015,16(1):245-251. [10] Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin vs doxorubicin as palliative chemo- therapy in patients with advanced hepatocel-lular carcinoma from Asia. J Clin Oncol,2013,31(28):3501-3508. [11] Longo V,Gnoni A,Casadei Gardini A,et al.Immuno-therapeutic approaches for hepatocellular carcinoma. Oncotarget,2017,8(20):33897-33910. [12] Waghray A,Murali AR,Narayanan Menon KV.Hepatocellular carcinoma:From diagnosis to treatment. World J Hepatol,2015,7(8):1020-1029. [13] Chang H,Jung W,Kim A,et al.Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1,and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. APMISM,2017,125(8):690-698. [14] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma. J Hepatol,2018[EPUD ahead of print]. [15] Yeh CH,Yang YY,Huang YF,et al.Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction.Chin JIntegr Med,2012,18(9):676-682. [16] Han D,Cao C,Su Y,et al.Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer. J Ethnopharmacol,2016,192:406-412. [17] Zhang HL,Yu LX,Yang W,et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol,2012,57:803-812 [18] Yang PY,Hu DN,Kao YH,et al.Norcantharidin induces apoptosis in human prostate cancer cells through both intrinsic and extrinsic pathways. Pharmacol Rep,2016,68(5):874-880. |